AI Verdict
RKLB has stronger fundamentals based on our AI analysis.
RLAY vs RKLB Fundamental Comparison
| Metric | RLAY | RKLB |
|---|---|---|
| Revenue | $15.4M | $601.8M |
| Net Income | $-276.5M | $-198.2M |
| Net Margin | -1,800.6% | -32.9% |
| ROE | -48.8% | -11.5% |
| ROA | -44.5% | -8.5% |
| Current Ratio | 22.61x | 4.08x |
| Debt/Equity | 0.00x | 0.09x |
| EPS | $-1.61 | $-0.37 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RLAY vs RKLB: Frequently Asked Questions
Is RLAY or RKLB a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RKLB has stronger fundamentals. RLAY is rated SELL (78% confidence) while RKLB is rated HOLD (63% confidence). This is not investment advice.
How does RLAY compare to RKLB fundamentally?
Relay Therapeutics, Inc. has ROE of -48.8% vs Rocket Lab Corp's -11.5%. Net margins are -1,800.6% vs -32.9% respectively.
Which stock pays higher dividends, RLAY or RKLB?
RLAY has a dividend yield of N/A or no dividend while RKLB has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RLAY or RKLB for long term?
For long-term investing, consider that RLAY has SELL rating with 78% confidence, while RKLB has HOLD rating with 63% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RLAY vs RKLB?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RLAY vs RKLB, the AI consensus favors RKLB based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.